Another Upgrade | ARWR Message Board Posts

Arrowhead Pharmaceuticals, Inc.

  ARWR website

  • To open or close the box of links at the top of your board, click the "hide/show" button to the right of your page, as shown here:


    To view a vertical list of all your board links on a separate page, click the "View Full List" link in parentheses.

    In the meantime, we will see what we can do to bring more attention to the "hide/show" button, such as making it bigger and/or adding color to it.

    Please continue sending constructive feedback via PM to Admin or email admin@investorvillage.com. We appreciate hearing from you!

ARWR   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  10071 of 10159  at  10/22/2019 9:15:48 AM  by

Manny


Another Upgrade

Arrowhead price target raised to $45 from $32 at Chardan Chardan analyst Keay Nakae increased his price target on Arrowhead shares to $45 from $32 following the company's R&D day last Friday, which he said illustrated the company success in rapidly advancing its pipeline assets. Based on the "benign" safety data and target knockdown data presented thus far from Phase 1 studies of AROANG3 and ARO-APOC3 targeting dyslipidemia and hyper-triglycerides, Nakae has increased his view of the odds of success for these programs to 25%, he noted. Nakae keeps a Buy rating on Arrowhead shares.



     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 4     Views: 324
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board






Financial Market Data provided by
.


Loading...